Skip to content
PCRS is set to issue a new circular clarifying the reimbursement of GLP-1 agonists under Community Drug Schemes for approved licensed use only.
We wish to remind members, that as set out in HSE PCRS Circular 022/20 Ozempic® and Victoza®, and now also Trulicity®, are not available for reimbursement under the Drug Payment Scheme. Reimbursement is confined to those persons with full GMS or LTI eligibility for the indicated use for the treatment of Type II Diabetes Mellitus.
Eligible patients should be registered under the LTI Scheme to obtain this product free of charge. The form can be downloaded here.
We are currently engaging with the PCRS regarding historic reimbursement claims for Trulicity dispensed in good faith under the DPS. Additionally, we have demanded that a grace period be established for provision of these medications under the DPS for newly prescribed patients to facilitate an application for reimbursement under LTI eligibility.
